Home/Publication/Qiming & Lilly Asia Fund Pulmonary Hypertension Solutions
Qiming & Lilly Asia Fund Pulmonary Hypertension Solutions 

03 Mar 2025

US$ 20.00

Qiming Venture Partners and Lilly Asia Ventures (LAV) have co-led the near US$100 million series C financing round ......

Price / article: US$20.00
OR existing subscriber
Related Publications

Subscribers’ Weekly ending 13 Jun 2025...

Listen to Rest of Asia/Rest of the World Investments (Subscribers' Weekly 13 Jun 2025)...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.